Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Trinity Biotech (TRIB) Net Margin (2016 - 2024)

Trinity Biotech's Net Margin history spans 16 years, with the latest figure at 99.62% for Q4 2024.

  • On a quarterly basis, Net Margin fell 5948.0% to 99.62% in Q4 2024 year-over-year; TTM through Dec 2024 was 49.82%, a 1409.0% increase, with the full-year FY2025 number at 85.36%, down 3372.0% from a year prior.
  • Net Margin hit 99.62% in Q4 2024 for Trinity Biotech, down from 31.64% in the prior quarter.
  • Over the last five years, Net Margin for TRIB hit a ceiling of 33.38% in Q3 2020 and a floor of 131.85% in Q2 2023.
  • Historically, Net Margin has averaged 28.47% across 5 years, with a median of 26.64% in 2024.
  • Biggest five-year swings in Net Margin: tumbled -13178bps in 2023 and later surged 8835bps in 2024.
  • Tracing TRIB's Net Margin over 5 years: stood at 31.62% in 2020, then plummeted by -155bps to 17.23% in 2021, then tumbled by -285bps to 66.4% in 2022, then skyrocketed by 40bps to 40.14% in 2023, then plummeted by -148bps to 99.62% in 2024.
  • Business Quant data shows Net Margin for TRIB at 99.62% in Q4 2024, 31.64% in Q3 2024, and 43.5% in Q2 2024.